Dr. Karl Thomae Gmbh

Boehringer Ingelheim Gmbh

Karl Thomae Gmbh

Dr. Karl Thomae Gesellschaft MIT Beschrankter Haftung

Boehringer Ingelheim Pharma Kg

Boehringer Ingelheim Pharmaceuticals, Inc.

Other

Boehringer Ingelheim Pharma Gmbh & Co Kg

Karl Thomas Gmbh

Wolfgang Eberlein

Wolfhard Engel

Henri Doods

Gerhard Mihm

Gunter Trummlitz

Klaus Rudolf

Joachim Heider

Volkhard Austel

Norbert Mayer

Rudolf Hammer

Gunther Schmidt

Walter Kobinger

Christian Lillie

Eberhard Kutter

Rudolf Kadatz

Michael Entzeroth

Willi Diederen

Adriaan De Jonge

Wolfgang Wienen

Piero Del Soldato

Gerhard Hallermayer

Jurgen Dammgen

Klaus-Dieter Willim

Gunther Engelhardt

Antonio Giachetti

Gunther Trummlitz

Helmut Pieper

Karl D Hargrave

Eckhart Bauer

Gunther Schmidt, Deceased

Heike-Andrea Wieland

Gu/ Nther Schmidt

Gu/ Nter Trummlitz

Horst Dollinger

Franz Esser

John Robert Proudfoot

Gerd Schnorrenberg

Walter Haarmann

Karl G Grozinger

Julian Adams

Rainer Zimmermann

Jurgen Krause

Harald Ziegler

Heike Andrea Wieland

Volkard Austel

Frank Himmelsbach

Norbert Hauel

Armin Heckel

Stephan Georg Mueller

Gerald Juergen Roth

Roland Maier

Rudolf Hurnaus

Manfred Reiffen

Wolfgang Grell

Rainer Walter

Uwe Lechner

Eberhard Woitun

Ernst Seeger

Walter Spevak

Johannes Keck

Hanns Goeth

Klaus Reinhold Noll

Bernd Wetzel

Gerd Kruger

Norbert Redemann

Alexander Dreyer

Ulrike Tontsch-Grunt

Joachim Kahling

Volker Trach

Wolfang Reuter

Gu/ Nther Trummlitz

Piero D Soldato

Welfhard Engel

Adrian De Jonge

Richard Reichl

Jacobus Ca Van Meel

Thomas Von Rueden

The present invention relates to modified amino acids of general formula whereinA, Z, X, n, m, R, R, R, Rand Rare defined as in claimsto, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

Modified amino acids, pharmaceuticals containing these compounds and method for their production

A compound of general formula (I) wherein R and Rare as defined herein, or a tautomer, diastereomer, enantiomer, or salt thereof, particularly the physiologically acceptable salts thereof, which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing the compound, their use, and processes for preparing them.

Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof

The present invention relates to compounds of general formulaR&#x2014;Z&#x2014;Z&#x2014;Z&#x2014;R, &#x2003;&#x2003;(I)wherein

Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof

The present invention relates to substituted piperidines of general formulawherein

Substituted piperidines, medicaments containing these compounds, and methods for the production thereof

The present invention relates to new substituted indolinones of general formulawherein The above compounds of general formula I wherein Rdenotes a hydrogen atom, a C-alkyl group or a prodrug group have valuable pharmacological properties, particularly an inhibiting effect on various kinases, on viral cyclin and on receptor tyrosine kinases, and the other compounds of the above general formula I wherein Rdoes not represent a hydrogen atom, a C-alkyl group or a prodrug group are valuable intermediate products for the preparation of the abovementioned compounds.

Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs

A method for treating menopausal hot flushes using CGRP antagonists and/or CGRP release inhibitors and the corresponding pharmaceutical compositions containing as active substance one or more CGRP antagonists and/or CGRP release inhibitors, and the preparation thereof.

Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes

Modified aminoacids, pharmaceuticals containing these compounds and method for their production

Antagonists of calcitonin gene-related peptide

NPY-antagonistic compounds of the formula ##STR1## Exemplary are: (A) (R)-N-[[4-(Aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -bis(4-hydroxyphenyl)acetyl]-argininamide-trifluoracetate;

Amino acid derivatives, pharmaceutical compositions containing these

Amino acid derivatives, medicaments containing said compounds and

Amino acid derivatives, suitable for the treatment of obesity. The following compound is exemplary of the class: (R,S)-N.sup.2 -(diphenylacetyl)-N-�(4-hydroxyphenyl)methyl!-N.sup.5 -(1H-imidazol-2-yl)-ornithinamide.

New condensed diazepinones of general formula I ##STR1## wherein B represents one of the divalent groups ##STR2## and X, l, m, n and R.sup.1 to R.sup.7 are as defined herein, as well as the salts thereof with inorganic or organic acids and processes for preparing them. These compounds are useful for improving or normalising arteriosclerotically induced disorders of cerebral blood flow, for treating diseases of the central nervous system, particularly Alzheimer's disease and Parkinson's disease, and as vagal pacemakers for treating bradycardia and bradyarrhythmia, and also for improving memory performance.

Condensed diazepinones, processes for preparing them and agents

Disclosed are novel 5,11-dihydro-6H-dipyrido[3,2-b; 2',3'-e][1,4]diazepines. These are useful in the prevention or treatment of HIV infection.

5,11-dihyro-6H-dipyrido[3,2-B:2',3'-e][1,3]diazepines and their use in

Amino acid derivatives, suitable for the treatment of obesity. The following compound is exemplary of the class: (R)-N2-(diphenylacetyl)-N-[(4-hydroxyphenyl) methyl]-argininamide-acetate.

Growing community of inventors

Biberach, Germany

Wolfgang Eberlein